Agilent Technologies, Inc. $A Shares Sold by Legacy Wealth Management LLC MS

Legacy Wealth Management LLC MS reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 74.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,873 shares of the medical research company’s stock after selling 20,332 shares during the period. Legacy Wealth Management LLC MS’s holdings in Agilent Technologies were worth $811,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Whipplewood Advisors LLC increased its holdings in shares of Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after buying an additional 186 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after buying an additional 192 shares in the last quarter. Stone House Investment Management LLC bought a new position in shares of Agilent Technologies in the first quarter valued at $30,000. Opal Wealth Advisors LLC bought a new position in shares of Agilent Technologies in the first quarter valued at $31,000. Finally, Ransom Advisory Ltd bought a new position in shares of Agilent Technologies in the first quarter valued at $32,000. 87.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is currently owned by insiders.

Agilent Technologies Stock Down 2.8%

A stock opened at $123.19 on Friday. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company has a market cap of $34.92 billion, a price-to-earnings ratio of 28.92, a PEG ratio of 3.94 and a beta of 1.24. The company has a 50 day moving average of $119.76 and a two-hundred day moving average of $115.99.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the prior year, the firm earned $1.32 EPS. The company’s revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Robert W. Baird upped their price target on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. UBS Group dropped their price target on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. JPMorgan Chase & Co. reduced their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday, May 29th. Wall Street Zen cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Barclays reiterated an “equal weight” rating and set a $125.00 price objective on shares of Agilent Technologies in a research report on Friday, August 29th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $139.25.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.